No quarterly revenue total was found in IN8BIO, INC.'s SEC filings.
IN8BIO, Inc. (INAB) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Sep 30, 2026 it held $14.0 million in cash and investments and $2.8 million in total debt.
Revenue
—
Net income
$-4.59M
-19.1% vs year-ago quarter
Operating cash flow
$-3.93M
-11.4% vs year-ago quarter
Free cash flow
$-3.52M
+10.3% vs prior quarter
EPS
$-0.24
+71.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
10.81M
+133.2% vs year-ago quarter
Net cash
$11.22M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- INAB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1740279
- Former names
- Incysus Therapeutics, Inc. (until Sep 20, 2018)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$4.6M | -$4.8M | -$5.1M | -$4.9M | -$3.9M |
| Net income | -$4.6M | -$4.8M | -$5.1M | -$4.9M | -$3.9M |
| Diluted EPS | -$0.24 | -$0.25 | -$0.26 | -$0.70 | -$0.85 |
| Operating cash flow | -$3.9M | -$3.7M | -$4.9M | -$2.1M | -$3.5M |
| Free cash flow | — | — | — | — | -$3.5M |
| Total assets | $18.7M | $21.7M | $26.3M | $32.3M | $16.8M |
| Total liabilities | $4.5M | $3.4M | $3.5M | $4.7M | $3.6M |
| Stockholders' equity | $14.2M | $18.4M | $22.8M | $27.6M | $13.2M |
| Cash and investments | $14.0M | $18.0M | $21.9M | $27.1M | $10.7M |
| Total debt | $2.8M | $2.2M | $2.4M | $2.8M | $3.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Jun 1, 2026 | May 29, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change, Shareholder vote results
|
May 7, 2026 | May 7, 2026 |
| ARS | Annual report to shareholders | Mar 26, 2026 | Dec 31, 2025 |
All 410 IN8BIO, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.